Clinical utility of the PFA-100

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 8, 2008, Pages 709-733

  Favaloro, Emmanuel J ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b SWAHS   (Australia)

Author keywords

Aspirin; PFA 100; Primary hemostasis; Von Willebrand disease; VWD

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIVITAMIN K; BERAPROST; CLOPIDOGREL; DESMOPRESSIN; EPTIFIBATIDE; ERYTHROPOIETIN; GADOTERIC ACID; GAMMA INTERFERON; HEPARIN; INDOMETACIN; IOPROMIDE; IOXAGLIC ACID; LICOFELONE; MELOXICAM; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROPOFOL; PROSTACYCLIN; RALOXIFENE; ROPIVACAINE; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; UNINDEXED DRUG; VALSARTAN; VON WILLEBRAND FACTOR; XENON;

AGE; ANALYTIC METHOD; ANALYZER; ANTICOAGULANT THERAPY; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESPONSE; GENDER; HEALTH CARE UTILIZATION; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HORMONAL THERAPY; HUMAN; NONHUMAN; ORAL CONTRACEPTION; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PREGNANCY; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY ANALYSIS; SMOKING; THROMBOCYTE FUNCTION; THROMBOSIS; VON WILLEBRAND DISEASE;

ASPIRIN; DRUG MONITORING; HEMOSTASIS; HUMANS; PLATELET FUNCTION TESTS; VON WILLEBRAND DISEASE;

EID: 60549104066     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1145254     Document Type: Review

References (174)

1. Alshameeri RS, Mammen EF. Clinical experience with the Thrombostat 4000. Semin Thromb Hemost 1995;21(Suppl 2):1-10
2. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-112
3. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(Suppl 2):113-121
4. Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterisation of an in-vitro Platelet Function Analyser, PFA-100®. Clin Appl Thromb Hemost 1996;2:241-249
5. Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997;87:159-164
6. Marshall PW, Williams AJ, Dixon RM, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997;44: 151-155
7. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
8. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
9. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73
10. Knöfler R, Weissbach G, Kuhlisch E. Platelet function tests in childhood. Measuring aggregation and release reaction in whole blood. Semin Thromb Hemost 1998;24:513-521
11. Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998;24:523-529
12. Suzuki S, Morishita S. Platelet hemostatic capacity (PHC) and fibrinolytic inhibitors during pregnancy. Semin Thromb Hemost 1998;24:449-451
13. Keidel A, Mischke R. Clinical evaluation of platelet function analyzer PFA-100 in dogs. Berl Munch Tierarztl Wochenschr 1998;111:452-456
14. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-S178
15. Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001;7:170-179
16. Favaloro EJ. Clinical application of the PFA-100®. Curr Opin Hematol 2002;9:407-415
17. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32:537-545
18. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100® and VWF:CB as coupled strategies. Semin Thromb Hemost 2006;32:566-576
19. Favaloro EJ, Bonar R, Duncan E, Rodgers S, Marsden K(on behalf of the RCPA QAP in Haematology). The utility of the PFA-100® as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand. Blood Coagul Fibrinolysis 2007;18:441-448
20. Duncan EM, Bonar R, Rodgers SE, Favaloro EJ, Marsden K. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. Int J Lab Hematol 2009; in press
21. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in haemostasis? Semin Thromb Hemost 2008;34:612-634
22. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163
23. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008;99:14-26
24. Dyszkiewicz-Korpanty A, Quinton R, Yassine J, Sarode R. The effect of a pneumatic tube transport system on PFA-100 closure time and whole blood platelet aggregation. J Thromb Haemost 2004;2:354-356
25. Bock M, De Haan J, Beck KH, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904
26. Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia 1999;44:661-665
27. Cho YU, Chi HS, Jang S, Park CJ. Reconfirmation of preanalytical variables and establishment of reference intervals of platelet function analyzer-100 closure times in Korean adults. Korean J Lab Med 2007;27:318-323
28. Brockmann MA, Beythien C, Magens MM, Wilckens V, Kuehnl P, Gutensohn K. Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated whole blood. Thromb Res 2001;104:333-342
29. Lippi G, Manzato F, Franchini M, Brocco G, Florenziani G, Guidi G. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001;1:69-70
30. Suzuki S, Morishita S. The relationship between the onset of labor mechanisms and the hemostatic system. Immunopharmacology 1999;43:133-140
31. Davies JR, Fernando R, Hallworth SP. Hemostatic function in healthy pregnant and preeclamptic women: an assessment using the platelet function analyzer (PFA-100) and thromboelastography. Anesth Analg 2007;104:416-420
32. Vincelot A, Nathan N, Collet D, Mehaddi Y, Grandchamp P, Julia A. Platelet function during pregnancy: an evaluation using the PFA-100 analyser. Br J Anaesth 2001;87:890-893
33. Marietta M, Castelli I, Piccinini F, et al. The PFA-100 system for the assessment of platelet function in normotensive and hypertensive pregnancies. Clin Lab Haematol 2001;23:131-134
34. Feuring M, Christ M, Roell A, et al. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002;13:443-447
35. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369-370
36. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001;86:880-886
37. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56-60
38. Feuring M, Harenberg J, Peiter A, et al. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function. Platelets 2005;16:430-434
39. Welsby IJ, Jones R, Pylman J, et al. Cardiothoracic Anesthesiology Research Endeavours. (C.A.R.E.). Blood ABO blood group and bleeding after coronary artery bypass graft surgery. Blood Coagul Fibrinolysis 2007;18:781-785
40. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets 2000;11:320-324
41. Pamukcu B, Oflaz H, Acar RD, et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J Thromb Thrombolysis 2005;20:17-22
42. Lippi G, Montagnana M, Salvagno GL, Franchini M, Guidi GC. Comparison of platelet function between sedentary individuals and competitive athletes at rest. Thromb J 2006;4:10
43. Aurigemma C, Fattorossi A, Sestito A, et al. Relationship between changes in platelet reactivity and changes in platelet receptor expression induced by physical exercise. Thromb Res 2007;120:901-909
44. Nimmerfall K, Mischke R. Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs. Dtsch Tierarztl Wochenschr 1999;106:439-444
45. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999;5:122-130
46. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321
47. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 2000;84:93-97
48. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007;115:996-1003
49. Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999;106:777-783
50. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39
51. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999;62:165-174
52. Meskal A, Vertessen F, Van der Planken M, Berneman ZN. The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease. Ann Hematol 1999;78:426-430
53. Kerenyi A, Schlammadinger A, Ajzner E, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999;96:487-492
54. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999;10:25-31
55. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in a paediatric-based population - comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen-bindiing assay. Thromb Haemost 2000;84:401-409
56. Schlammadinger A, Kerenyi A, Muszbek L, Boda Z. Comparison of the O'Brien filter test and the PFA-100 platelet analyser in the laboratory diagnosis of von Willebrands disease. Thromb Haemost 2000;84:88-92
57. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 2000;84:93-97
58. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189
59. Harrison P, Robinson M, Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 2002;24:225-232
60. Buyukasik Y, Karakus S, Goker H, et al. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 2002;13:349-353
61. Wuillemin WA, Gasser KM, Zeerleder SS, Lämmle B. Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly 2002;132:443-448
62. Nitu-Whalley IC, Lee CA, Brown SA, Riddell A, Hermans C. The role of the platelet function analyser (PFA-100) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group. Haemophilia 2003;9:298-302
63. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003;25:474-479
64. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003;90:483-490
65. Favaloro EJ. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients - a rebuttal. J Thromb Haemost 2004;2:2280-2282
66. Quiroga T, Goycoolea M, Muñoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. Thromb Haemost 2004;2:892-898
67. Koscielny J, Ziemer S, Radtke H, et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:195-204
68. Philipp CS, Miller CH, Faiz A, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia 2005;11:497-503
69. Penas N, Pérez-Rodríguez A, Torea JH, et al. Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia) Am J Hematol 2005;80:188-196
70. Favaloro EJ, Lloyd J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost 2007;97:922-930
71. Perel JM, Just S, Rowell J, Williams B, Kennedy GA. Utility of the PFA-100 analyser in the evaluation of primary haemostasis in a paediatric population. Int J Lab Hematol 2007;29:480-481
72. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007;5:2393-2398
73. Favaloro EJ, Patterson D, Denholm A, et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease from type 2B VWD using a simplified ristocetin-induced-platelet-agglutination (RIPA) mixing assay and confirmed by genetic analysis. Br J Haematol 2007;139:623-626
74. Karger R, Donner-Banzhoff N, Müller HH, Kretschmer V, Hunink M. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history-a systematic review and meta-analysis. Platelets 2007;18:249-260
75. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007;92:1647-1654
76. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189
77. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670
78. Koscielny J, von Tempelhoff GF, Ziemer S, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:155-166
79. Franchini M, Zugni C, Veneri D, et al. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica 2004;89:1341-1346
80. Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Semin Thromb Hemost 2006;32:636-645
81. Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Haemophilia 2008;14:524-530
82. Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia 2008;14:571-578
83. van Vliet HHDM, Kappers-Klunne MC, Leebeek FWG et al. PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008;100:462-468
84. Favaloro EJ. A better approach to monitoring of therapy in von Willebrand disease? Thromb Haemost 2008;100:371-373
85. Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999;96:213-217
86. Harrison C, Khair K, Baxter B, Russell-Eggitt I, Hann I, Liesner R. Hermansky-Pudlak syndrome: infrequent bleeding and first report of Turkish and Pakistani kindreds. Arch Dis Child 2002;86:297-301
87. Liang HP, Morel-Kopp MC, Curtin J, et al. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients. Thromb Haemost 2007;98:1298-1308
88. Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom 2008;74:194-199
89. Francis J, Francis D, Larson L, Helms E, Garcia M. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999;10:132-136
90. Wahba A, Sander S, Birnbaum DE. Are in-vitro platelet function tests useful in predicting blood loss following open heart surgery? Thorac Cardiovasc Surg 1998;46:228-231
91. Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron JF, Aiach M. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000;84:794-799
92. Forestier F, Coiffic A, Mouton C, Ekouevi D, Chêne G, Janvier G. Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth 2002;89:715-721
93. Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003;90:692-693
94. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-57
95. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004;92:178-186
96. Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005;31:426-440
97. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001;141:226-233
98. Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002;144:151-158
99. Van der Planken MG, Claeys MJ, Vertessen FJ, et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003;111:159-164
100. Konopka A, Spychalska J, Sitkiewicz D, et al. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone. Am J Cardiovasc Drugs 2007;7:433-439
101. van Werkum JW, Gerritsen WB, Kelder JC, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J 2007;15:375-381
102. de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 1999;66:425-430
103. van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol 2002;53:644-647
104. Fischetti D, Sciahbasi A, Leone AM, et al. Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions. J Thromb Thrombolysis 2000;10:265-269
105. Fattorutto M. Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation. Am Heart J 2003;146:E8
106. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AKThe Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-329
107. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6:444-450
108. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599
109. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-198
110. Reny JL, Quéré I, de Moerloose P, Fontana P. Aspirin response variability assessed with the PFA-100 device. Thromb Haemost 2008;99:968-969
111. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. Rebuttal to "Aspirin response variability assessed with the PFA-100 device" by Reny et al. Thromb Haemost 2008;99:969
112. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129-1131
113. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002;13:493-497
114. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849-854
115. Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 2003;37:117-123
116. Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003;34:849-854
117. Lepäntalo A, Virtanen KS, Heikkilä J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:476-483
118. Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004;2:2278-2279
119. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005;51:957-965
120. Mani H, Linnemann B, Luxembourg B, Kirchmayr K, Lindhoff-Last E. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006;17:303-310
121. Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006;105:676-683
122. Alström U, Tydén H, Oldgren J, Siegbahn A, Ståhle E. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb Res 2007;120:353-359
123. Serebruany VL, Malinin AI, Atar D. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. Cardiology 2007;107:307-312
124. Lev EI, Ramchandani M, Garg R, et al. Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. J Thromb Thrombolysis 2007;24:15-21
125. Malek LA, Grabowski M, Spiewak M, et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. J Thromb Thrombolysis 2007;24:301-305
126. Kotzailias N, Elwischger K, Sycha T, et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis 2007;16:199-202
127. Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, Sarode R. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). Platelets 2007;18:491-496
128. Konopka A, Spychalska J, Sitkiewicz D, et al. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone. Am J Cardiovasc Drugs 2007;7:433-439
129. Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am Heart J 2008;155:93.e1-97
130. Fehr M, Galliard-Grigioni KS, Reinhart WH. Influence of acute alcohol exposure on hemorheological parameters and platelet function in vivo and in vitro. Clin Hemorheol Microcirc 2008;39:351-358
131. Pearson DA, Paglieroni TG, Rein D, et al. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002;106:191-197
132. Bordeaux B, Yanek LR, Moy TF, et al. Casual chocolate consumption and inhibition of platelet function. Prev Cardiol 2007;10:175-180
133. Scharbert G, Kalb ML, Duris M, Marschalek C, Kozek-Langenecker SA. Garlic at dietary doses does not impair platelet function. Anesth Analg 2007;105:1214-1218
134. Beckert BW, Concannon MJ, Henry SL, Smith DS, Puckett CL. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007;120:2044-2050
135. Kwok Y, Ng KF, Li CC, Lam CC, Man RY. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 2005;101:423-426
136. Golański J, Muchova J, Golański R, Durackova Z, Markuszewski L, Watała C. Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience Postepy Hig Med Dosw (Online) 2006;60:316-321
137. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. Dark chocolate: consumption for pleasure or therapy? J Thromb Thrombolysis 2008; Sept 23 [Epub ahead of print]
138. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question Circulation 2007;116:1306-1317
139. Marietta M, Castelli I, Piccinini F, et al. The PFA-100 system for the assessment of platelet function in normotensive and hypertensive pregnancies. Clin Lab Haematol 2001;23:131-134
140. Vincelot A, Nathan N, Collet D, Mehaddi Y, Grandchamp P, Julia A. Platelet function during pregnancy: an evaluation using the PFA-100 analyser. Br J Anaesth 2001;87:890-893
141. Davies JR, Fernando R, Hallworth SP. Hemostatic function in healthy pregnant and preeclamptic women: an assessment using the platelet function analyzer (PFA-100) and thromboelastograph. Anesth Analg 2007;104:416-420
142. Nemmar A, Hoylaerts MF, Hoet PH, Vermylen J, Nemery B. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol 2003;186:38-45
143. Nemmar A, Hoet PH, Dinsdale D, Vermylen J, Hoylaerts MF, Nemery B. Diesel exhaust particles in lung acutely enhance experimental peripheral thrombosis. Circulation 2003;107:1202-1208
144. Nemmar A, Nemery B, Hoet PH, Vermylen J, Hoylaerts MF. Pulmonary inflammation and thrombogenicity caused by diesel particles in hamsters: role of histamine. Am J Respir Crit Care Med 2003;168:1366-1372
145. Nemmar A, Hoylaerts MF, Hoet PH, Nemery B. Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol Lett 2004;149:243-253
146. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Air pollution and coagulation testing: a new source of biological variability? Thromb Res 2008;123:50-54
147. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-619
148. Pihusch R, Rank A, Göhring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002;37:548-555
149. Bilgin AU, Karadogan I, Artac M, Kizilors A, Bligin R, Undar L. Hemodialysis shortens long in vitro closure times as measured by the PFA-100. Med Sci Monit 2007;13:CR141-CR145
150. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-1397
151. Sestito A, Sgueglia GA, Spinelli A, et al. Increased platelet reactivity in unstable angina patients is not related to Creactive protein levels. Platelets 2006;17:336-339
152. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006;4:2043-2050
153. Fuchs I, Frossard M, Spiel A, Riedmüller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-2552
154. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008;196:341-348
155. Linden MD, Furman MI, Frelinger AL III, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761-765
156. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 2008;25:207-213
157. Jacopo G, Elisabetta V, Silverio S, et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007;121:407-412
158. Jilma-Stohlawetz P, Jilma B, Mannhalter C, et al. Platelet glycoprotein Ibalpha polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease. Ann Hematol 2007;86:719-725
159. Harrison P, Mackie I, Mathur A, et al. Platelet hyperfunction in acute coronary syndromes. Blood Coagul Fibrinolysis 2005;16:557-562
160. Franchini M, Lippi G. Von Willebrand factor and thrombosis. Ann Hematol 2006;85:415-423
161. Franchini M, Mannucci PM. Von Willebrand factor: another Janus-faced hemostasis protein. Semin Thromb Hemost 2008;34:663-669
162. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004;124:80-85
163. Kilanowska J, Favaloro EJ, Lippi G. Aspirin 'responsiveness,' 'non-responsiveness' or 'resistance': a putative role for von Willebrand factor? Blood Coagul Fibrinolysis 2008;19:823-824
164. Favaloro EJ. An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult. Semin Thromb Hemost 2007;33:727-744
165. Favaloro EJ, Lippi G, Franchini M. Preface: laboratory diagnostics in thrombosis and hemostasis: the past, the present, and the future. Semin Thromb Hemost 2008;34:579-584
166. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008;34:604-611
167. Watson HG, Greaves M. Can we predict bleeding? Semin Thromb Hemost 2008;34:97-103
168. Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008;140:496-504
169. Karon BS, Wockenfus A, Scott R, et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 2008;54:1060-1065
170. Klein Gunnewiek JM, Hovestad-Witterland AH, Vollaard EJ, Fleuren HW, de Metz M. The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. Blood Coagul Fibrinolysis 2005;16:337-340
171. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005;130:759-767
172. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jørgensen B. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 2007;120:161-172
173. Carcao MD, Blanchette VS, Stephens D, et al. Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100). Br J Haematol 2002;117:961-964
174. Kretschmer V, Bade S, Weippert-Kretschmer M, Kratzer MA. Measurement of primary haemostasis using a pressure clamp technique. Platelets 2001;12:462-470